CompanyHealthEnterprise
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company in Cambridge, Massachusetts developing next-generation targeted radiotherapies for cancer. Its lead candidate, CONV01-α, is a PSMA-targeted monoclonal antibody linked to the alpha-emitting radioisotope actinium-225, designed to deliver tumor-killing radiation to metastatic castration-resistant prostate cancer while sparing healthy tissue. The technology, pioneered in the lab of PSMA-targeting pioneer Dr. Neil Bander and licensed from Cornell University, is led by oncologist Dr. Philip Kantoff.
2020Founded
CambridgeHQ
$132.5 million total funding (per Apollo data)Reported additional / total financing
radiopharmaceuticalstargeted-alpha-therapyactinium-225psmaprostate-cancerradioantibody